About Emergency Contraceptive (EC) Pills
EC pills are short-term contraceptives used in the initial days after sexual intercourse to prevent pregnancy due to various uncertainties such as unprotected intercourse, coerced sex, forgotten pills, and condom breakage. These pills are only effective before the fertilization of the ovum by the sperm. As per WHO, levonorgestrel-based EC pills are ideal for users when taken in a single dose. These pills are not effective after five days once the ovulation process begins. Factors such as urbanization, increasing acceptance of sex, and growing visibility of EC pills are increasing their penetration in emerging economies.
Technavio’s analysts forecast the global EC pills market to grow at a CAGR of 1.93% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global EC pills market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the retail sales of generic and branded EC pills worldwide. However, the report does not include sales of long-term contraception methods such as birth control pills.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Emergency Contraceptive (EC) Pills Market 2016-2020
Technavio recognizes the following companies as the key players in the global emergency contraceptive (EC) pills market: Allergan, Lupin Pharmaceuticals, Mankind Pharma, Piramal Healthcare, and Teva Pharmaceuticals.
Other Prominent Vendors in the market are: HLL Life Care, Pfizer, Syzygy Healthcare, and V Care Pharma.
Commenting on the report, an analyst from Technavio’s team said: “Growing sales of generic brands will be a key trend for the market growth. Generic EC pills are increasingly being sold at different drug stores. Compared with branded EC pills, the generic EC pills are less costly and available to all with no age limit. These factors have led to increased sales of generic brands. For instance, Teva Pharmaceuticals generates the majority of its revenue from its generic brand Plan B, rather than its original brand, which is usually sold through pharmacy counters and requires a prescription for women under the age of 17. Thus, vendors are trying to implement push marketing for increasing sales and directly contribute to the revenue of the market during the forecast period.”
According to the report, rise in exploration of sexual fantasies will be a key driver for market growth. Globally, there has been an increase in the exploration of sexual fantasies. Sexual norms, behaviors, and attitudes are undergoing a transformation because of increased exposure to the internet, TV shows, and erotic literature. This has also paved the way for casual sex with multiple partners. The younger generation is embracing experimentation when it comes to sex and is aware of the protection required. This is driving the demand for EC pills in the markets as they are effective and reliable in preventing pregnancy. The shift in the attitude of consumers is evident because, despite the economic slowdown, there are new players as well as niche players in the market.
Further, the report states that doubts regarding effectiveness will be a major challenge for the market. EC pills in the market claim to be almost 100% effective if the procedure of use is followed precisely, irrespective of the time. In rare occasions, these pills fail to act, owing to delay in use or other reasons, bringing into question the reliability of the product. The results of EC pills vary on the basis of use – the sooner the user takes the pill, the more effective it is. The probability of getting effective results is high within 5 days after unprotected sexual intercourse and other uncertainties. Pills if taken beyond the given duration might not be 100% effective. Vendors in the market are working toward combating this challenge by developing more sensitive tests that can give effective results.
Allergan, Lupin Pharmaceuticals, Mankind Pharma, Piramal Healthcare, Teva Pharmaceuticals, HLL Life Care, Pfizer, Syzygy Healthcare, V Care Pharma.